Evidence map›Paper›PMID 31140729›Full record

ArticleJournal of cellular and molecular medicine2019

Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-α-Smurf1-Akt-mTOR-P70S6K pathway.

Jiajun Zhou, Hong Cheng, Zijie Wang, Hao Chen, Chuanjian Suo, Hengcheng Zhang, Jiayi Zhang, Yanhao Yang, Liang Geng, Ming Gu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The role of PI3K/Akt signaling pathway in chronic kidney disease.International urology and nephrology · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Bortezomib Inhibits Lung Fibrosis and Fibroblast Activation without Proteasome Inhibition.American journal of respiratory cell and molecular biology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jiajun ZhouDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Hong ChengDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Zijie WangDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Hao ChenDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Chuanjian SuoDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Hengcheng ZhangDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Jiayi ZhangDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Yanhao YangDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Liang GengDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Ming GuDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Ruoyun TanDepartment of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-2973-1558
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allograft interstitial fibrosis was characterized by massive extracellular matrix deposition caused by activated fibroblasts and myofibroblasts. Epithelial-mesenchymal transition (EMT) is recognized as an important source of myofibroblasts contributing to the pathogenesis of allograft interstitial fibrosis. Smad ubiquitination regulatory factor 1 (Smurf1) has been recently reported to be involved in the progression of EMT. Our study was to detect the effect of Bortezomib and Smurf1 in the EMT and allograft interstitial fibrosis. Biomarkers of EMT, as well as Smurf1, were examined in human proximal tubular epithelial cells (HK-2) treated with tumour necrosis factor-alpha (TNF-α) in various doses or at various time points by Western Blotting or qRT-PCR. We knockdown or overexpressed Smurf1 in HK-2 cells. Furthermore, rat renal transplant model was established and intervened by Bortezomib. Allograft tissues from human and rats were also collected and prepared for HE, Masson's trichrome, immunohistochemical staining and western blotting assays. As a result, we found that TNF-α significantly promoted the development of EMT in a time-dependent and dose-dependent manner through Smurf1/Akt/mTOR/P70S6K signalling pathway. More importantly, Bortezomib alleviated the progression of EMT and allograft interstitial fibrosis in vivo and in vitro by inhibiting the production of TNF-α and expression of Smurf1. In conclusion, Smurf1 plays a critical role in the development of EMT induced by TNF-α. Bortezomib can attenuate the Sumrf1-mediated progression of EMT and renal allograft interstitial fibrosis, which could be suggested as a novel choice for the prevention and treatment of renal allograft interstitial fibrosis.

Indexed as

AnimalsBortezomibCell LineEpithelial-Mesenchymal TransitionFibrosisHumansKidneyKidney DiseasesKidney TransplantationMaleProto-Oncogene Proteins c-aktRatsRats, Inbred F344Rats, Inbred LewRibosomal Protein S6 Kinases, 70-kDaSignal TransductionBortezomibProto-Oncogene Proteins c-aktRibosomal Protein S6 Kinases, 70-kDaTOR Serine-Threonine KinasesTumor Necrosis Factor-alphaUbiquitin-Protein LigasesAkt/mTOR/p70S6KBortezomibchronic allograft dysfunctionEMTkidney interstitial fibrosiskidney transplantationSmurf1

Identifiers

PMID31140729
PMCPMC6653435
OpenAlexW2946959514

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.